Europe (Denmark, UK, Spain, or other major hub)

In rare disease, access decisions often depend on evidence generated under difficult conditions: small populations, limited head-to-head data, and evidence expectations that vary across markets. In this role, you will turn that complexity into statistical strategies that are scientifically credible, transparent and fit for HTA and payer decision-making.

Your new role

You will lead strategic HTA statistics across our rare disease portfolio, where methodological complexity meets high-stakes evidence generation and every statistical choice matters.

Rare disease HTA presents challenges that often require more than standard approaches. You will develop statistical strategies for comparative effectiveness where populations are small, direct comparative data may be limited, and every piece of evidence needs to work harder. As EU HTA joint clinical assessments reshape evidence requirements across Europe, you will...